Why choose our CGT lawyers?
Even though CGT is attracting significant attention from various stakeholders, the route to market is far from straightforward with businesses having to overcome significant legal bottlenecks along the way to get treatments to patients.
Fieldfisher's pan-European life sciences lawyers have an in-depth
understanding of the CGT space. We have a wealth of experience working with and
advising the key players involved in the process from lab to patient on an
international scale, from ambitious ATMP producers, usually academic
institutions to development and manufacturing partners, larger pharmaceutical
and biotechnology companies, investors, regulators and industry lobby groups.
With experts across regulatory, intellectual property, data
protection, commercial and corporate law, we take a holistic approach to
working with clients at every stage of their CGT journey.
White paper – The future of medicine: Cell and gene therapy
In this paper we look at the cell and gene therapy landscape
across key hotspots in Europe, examining the opportunities and challenges for
those involved, particularly the regulatory and commercial law issues blocking
the pathway from lab to patient. This paper also discusses how national
healthcare providers across Europe are opening their eyes and pockets to the
substantial cost-savings that CGT can provide and with this shift in approach,
we look at what this means for the future of CGT in the UK and across
the rest of Europe.